Experts are hopeful that this preventive medication, taken before any exposure to COVID-19, will provide an extra layer of protection to those who may not mount a full immune response to the vaccine - Kelsey Kloss
image by: The Elliot Lewis Center
What to Know About Evusheld, the New Monoclonal Antibody Drug to Prevent COVID-19 in the Immunocompromised
Over the course of the pandemic, many immunocompromised patients have not been able to rejoin activities, events, and travel as fully as the general population — even if they’re fully vaccinated. That’s because people with certain underlying conditions or who take medications that affect their immune system might not mount a full response to the COVID-19 vaccine.
But now, the U.S. Food & Drug Administration (FDA) has issued an emergency use authorization (EUA) for long-acting monoclonal antibodies that can be used to prevent COVID-19 before exposure in immunocompromised individuals.
This product, AstraZeneca’s Evusheld, contains tixagevimab and cilgavimab — monoclonal antibodies…